News & Updates | The Sage Group

Sage Group News

BullFrog AI Partners with the Sage Group to Explore JV Opportunities to Advance its Oncology Assets

BullFrog’s oncology assets have been acquired through exclusive licenses with Johns Hopkins University (JHU) and include a Phase 2 ready...

The Sage Group advised Zhimeng Biopharma on a worldwide license to GSK of CB06-036, a TLR8 Agonist

In December 2022, GSK entered into an exclusive license agreement with biopharma company Zhimeng for CB06-036, a TLR8 agonist. Subject to...

AeroNeph Therapeutics Announces Search for Strategic Partners for Novel Drugs for Renal Disease

Birmingham, Alabama, and London, England, 1 September 2022 – AeroNeph Therapeutics (“AeroNeph”; www.aeroneph.com), a pioneer in discovery...

Eurofins Discovery Announces Aquisition of Sage Client Discovery BioMed

See full Press Release by clicking the link below!

Kinnov Therapeutics Completes Successful Phase 2 study for Alcohol Use Disorder

Sage’s new client, Kinnov Therapeutics, is a French-based company focused on one of the major unmet global healthcare challenges,...

Hatchtech appoints Sage Group to divest its FDA-approved Xeglyze® for head lice treatment

Hatchtech has engaged the Sage Group to manage the sale process for its lead asset Xeglyze®. Xeglyze is a patent protected, single...

Sage Advises Cancer Prevention Pharmaceuticals on Merger with Panbela Therapeutics

Product Opportunity for Rare Hematological Disease - KDFX for Iron Overload Disorder from Dispersol

Our new client DisperSol Technologies, Inc. (https://www.dispersoltech.com/) is a private, Austin, Texas-based drug development company...